Weight Loss With Injectable Semaglutide
Obesity is a chronic metabolic condition associated with increased cardiometabolic risk, particularly when accompanied by central adiposity, prediabetes and dyslipidaemia. For patients who have not achieved sustained weight reduction through lifestyle measures alone, pharmacological treatment may be considered as part of a comprehensive weight-management programme.
This case describes a 42-year-old female who achieved clinically meaningful weight loss over 12 months following treatment with once-weekly injectable semaglutide combined with structured dietary and lifestyle interventions.
Patient Information
- Age/Sex: 42-year-old female
- Height: 162 cm
- Baseline Weight: 96 kg
- Baseline BMI: 36.6 kg/m²
- Waist Circumference: 108 cm
Risk Status
The patient was considered to have high cardiometabolic risk due to:
- Class II obesity
- Central adiposity
- Prediabetes
- Dyslipidaemia
- Sedentary lifestyle
Presenting Complaints
The patient presented with:
- Progressive weight gain over the previous 6 years
- Increased abdominal obesity
- Easy fatigability
- Difficulty losing weight despite repeated dietary attempts
- Reduced physical activity
- Increased appetite, particularly in the evening
Medical History
The patient had a history of:
- Prediabetes
- Dyslipidaemia
- Sedentary lifestyle
- Multiple unsuccessful attempts at lifestyle-based weight reduction
- No previous bariatric surgery
- No history suggestive of pancreatitis or gallbladder disease
Diagnostic Assessment
Baseline Investigations
Parameter | Baseline |
Fasting glucose | 112 mg/dL |
HbA1c | 6.00% |
Triglycerides | 214 mg/dL |
LDL-C | 138 mg/dL |
ALT | 52 U/L |
Blood pressure | 138/86 mmHg |
The baseline findings indicated obesity with associated metabolic risk factors, including prediabetes and dyslipidaemia.
Therapeutic Intervention
After assessment for contraindications and discussion of available treatment options, once-weekly injectable semaglutide was initiated alongside a structured lifestyle programme.
Medication
The treatment plan included:
- Semaglutide 0.25 mg subcutaneously once weekly initially
- Gradual dose escalation according to tolerability and clinical response
- Monitoring for gastrointestinal adverse effects and other clinically relevant complications
Dose escalation should follow the locally approved product labelling and be individualised according to patient response and tolerability.
Lifestyle Intervention
The patient received structured counselling regarding:
- Calorie-controlled diet
- Adequate protein intake
- Increased vegetables and dietary fibre
- Reduction in refined carbohydrates and sugar-sweetened beverages
- Portion control
- At least 150 minutes of moderate physical activity per week
- Resistance exercise 2 to 3 times per week
- Adequate sleep and behavioural modification
Follow-Up and Weight Reduction
One-Year Outcome
After 12 months of treatment:
- Weight loss: 17.5 kg
- Percentage total body-weight loss: 18.2%
- Waist circumference: Reduced from 108 cm to 91 cm
The patient achieved substantial weight reduction accompanied by a decrease in waist circumference.
Adverse Effects
During the dose-escalation period, the patient experienced:
- Mild nausea
- Early satiety
- Occasional constipation
These symptoms were transient and improved with smaller meals, slower eating, adequate hydration and appropriate dietary adjustments.
No serious adverse events were reported.
Clinical Outcome
After 12 months of treatment, the patient achieved 17.5 kg of weight loss, representing an 18.2% reduction in baseline body weight. This was accompanied by a substantial reduction in waist circumference and improvement in glycaemic and lipid parameters.
The patient was advised that obesity is a chronic disease and that long-term weight-maintenance treatment and continued lifestyle modification may be necessary.
Key Learning Points
- Injectable semaglutide can produce clinically meaningful weight loss in appropriately selected patients with obesity.
- Pharmacotherapy works best as part of a comprehensive lifestyle programme.
- Gradual dose escalation can help improve gastrointestinal tolerability.
- Weight, waist circumference, glycaemic parameters and adverse effects should be monitored regularly.
- Appropriate patient selection and screening for contraindications are essential.
- Weight regain may occur after discontinuation of effective anti-obesity pharmacotherapy.
- Treatment goals should include improvements in health, metabolic risk and functional capacity, rather than focusing only on body weight.
Discussion
This case demonstrates the potential role of once-weekly injectable semaglutide as part of a comprehensive obesity-management strategy. Over one year, the patient achieved an 18.2% reduction in baseline body weight and a substantial reduction in waist circumference.
The treatment was combined with dietary modification, regular physical activity and behavioural changes. Mild gastrointestinal symptoms occurred during dose escalation but were transient and managed through dietary adjustments and appropriate treatment modification.
Conclusion
This case highlights the importance of combining pharmacological treatment with sustainable lifestyle changes when managing obesity. Regular monitoring, appropriate dose escalation and long-term weight-maintenance planning are important components of ongoing care.
For professional medical guidance, weight-management assessment or personalised obesity care, please contact us to connect with the healthcare team.
Note: This case study is for illustrative and educational purposes only and should not replace professional medical advice. If you have concerns about your weight or metabolic health, please consult a qualified healthcare provider.
